INTRODUCTION
serum calcium -9.2 mg/dl (8.4-10.4 ), T3-1.2 ng/ml (0.6-2.00), T4-8.4 μg/ml (5-12), thyroid stimulating hormone -2.7 mIU/ml (0.3-5.5), serum GH -10.8 ng/ ml (with clonidine stimulation), insulin-like growth factor-I -147 ng/ml (183-850) karyotyping -46 × Y. His bone age was 10 years determined by Greulich and Pyle chart. Psychological assessment by Binet Kamat test for intelligence was patient mental age 6 years 10 months; intelligence quotient (IQ) was 67 suggestive of mild mental retardation.
Department of Genetics evaluated this patient with the above features of disproportionate short stature, mild mental retardation, triangular facies, maxillary hypoplasia, short neck, hypoplastic ear lobes, drooping shoulders, clinodactyly, single palmar crease, and shawl scrotum patient was diagnosed to have Aarskog-Scott syndrome.
Patient was started on GH therapy along with rehabilitation program and genetic counseling of family done. The patient is doing well on GH therapy gained about 10 cm in 1 st year with SDS − 2.5.
DISCUSSION
In Aarskog-Scott syndrome (facial-digital-genital syndrome), males are typically more severely affected than females. A diagnosis made by clinical criteria. The primary criteria include those manifestations that are consistently present in more than 80% of patients, and the secondary criteria are those that are present in 50-70% of patients.
The primary diagnostic criteria [1] includes short stature, hypertelorism, a broad nasal bridge, a short nose with anteverted nares, a long philtrum, maxillary hypoplasia with or without malocclusion, a crease below the lower lip, abnormal auricles with fleshy lobules, short and broad hands, short fifth fingers with clinodactyly and a shawl scrotum. Secondary criteria include: Widow's peak hair pattern, ptosis, downward slanting palpebral fissures, joint hyperextensibility, broad feet with bulbous toes, cryptorchidism, inguinal hernia, and mild interdigital webbing.
Other features include short neck with reduced mobility, cleft lip, cleft palate. [2] Ophthalmological findings include strabismus, ophthalmoplegia, large cornea, esotropia, nystagmus, count -5600/cmm (4-11,000), erythrocyte sedimentation rate -15 (9) (10) (11) (12) (13) (14) , fasting blood sugar -89 mg% (80-110), serum creatinine -0.8 mg/dl (0.8-1.4), corrected and amblyopia. [3] Dental findings include delayed eruption of permanent teeth, retarded dental age, hypodontia and dental malocclusion, enamel hypoplasia, [4] and overcrowded teeth. [5] Cardiac defects include pulmonary stenosis and ventricular septal defects. [6] Intelligence is reported as normal or in the mildly retarded range. [7] IQ range 68-128 reported. [8] As stated earlier, this syndrome is partially expressed in girls, which consists mainly of short stature, short and broad hands and feet, and mild facial features. [1, 9] Clitoral hypertrophy has been reported. [10] Radiological findings include short tubular bones with broad metaphyses, brachyphalangy, hypoplastic middle phalanges of the fifth finger, pelvic hypoplasia, [11] anomalies of the cervical vertebrae, which consist of hypoplasia, synostosis, or spina bifida occulta, [12] delay in ossification centers and brachycephaly. The differential diagnosis includes Robinow and Noonan syndromes.
Molecular genetics
Mode of inheritance is X-linked recessive in most cases [7, 13] rarely autosomal dominant. [14, 15] Mutations in faciogenital dysplasia gene 1 have been mapped to chromosome Xp11.21. [16] However, mutations in other genes reported as well.
Short stature in Aarskog syndrome
Disproportionate short stature with an increased upper to lower segment ratio seen in 90% patients of AS. [1, 17, 18] Growth failure will be evident clinically by 3 years of age. Growth is slow during childhood. Puberty is usually delayed with a delayed bone age and pubertal height gain is suppressed. [17] Final height is reported to be between 150 cm and 160 cm in male patients, and between 140 cm and 150 cm in females, corresponding to a height SDS of approximately − 2.5. [13, 17] These patients are generally not GH deficient.
Experience with growth hormone in Aarskog syndrome available data
There is one report of a large series of 19 (16 male) AS patients treated with GH. [19] GH was given at a dose of 0.3 ± 0.07 mg/kg/week over 1.4-8.8 years. Height SDS increased by 1.0 ± 0.8 over a mean of 4 years of therapy started at a mean age of 10.5 years. Those patients (n = 6) who have completed GH treatment gained a median height SDS of 1.2 (0.3-2.8) . The median final height was 167.8 cm, ranging from 160 to 170.2 cm. There were no side-effects, except for gynecomastia and hepatomegaly in one case.
